Celldex Therapeutics Inc (NASDAQ: CLDX) is -5.07% lower on its value in year-to-date trading and has touched a low of $22.17 and a high of $53.18 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CLDX stock was last observed hovering at around $23.15 in the last trading session, with the day’s gains setting it 0.84%.
Currently trading at $23.99, the stock is -1.56% and -5.82% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.14 million and changing 3.63% at the moment leaves the stock -26.90% off its SMA200. CLDX registered -32.50% loss for a year compared to 6-month loss of -26.68%. The firm has a 50-day simple moving average (SMA 50) of $25.52 and a 200-day simple moving average (SMA200) of $32.8888.
The stock witnessed a -10.52% gain in the last 1 month and extending the period to 3 months gives it a -6.58%, and is -5.96% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.33% over the week and 6.05% over the month.
Celldex Therapeutics Inc (CLDX) has around 160 employees, a market worth around $1.59B and $9.98M in sales. Profit margin for the company is -1544.48%. Distance from 52-week low is 8.23% and -54.89% from its 52-week high. The company has generated returns on investments over the last 12 months (-19.56%).
with sales reaching $1.31M over the same period.The EPS is expected to grow by 15.25% this year, but quarterly earnings will post -0.78% year-over-year. Quarterly sales are estimated to shrink -68.37% in year-over-year returns.
251.0 institutions hold shares in Celldex Therapeutics Inc (CLDX), with institutional investors hold 108.35% of the company’s shares. The shares outstanding are 66.34M, and float is at 64.70M with Short Float at 13.11%. Institutions hold 108.03% of the Float.
The top institutional shareholder in the company is WELLINGTON MANAGEMENT GROUP LLP with over 8.08 million shares valued at $298.89 million. The investor’s holdings represent 13.718 of the CLDX Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 7.83 million shares valued at $289.76 million to account for 13.2988 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 4.69 million shares representing 7.9679 and valued at over $173.61 million, while VANGUARD GROUP INC holds 6.3512 of the shares totaling 3.74 million with a market value of $138.38 million.
Celldex Therapeutics Inc (CLDX) Insider Activity
The most recent transaction is an insider purchase by Marucci Anthony S, the company’s PRESIDENT & CEO. SEC filings show that Marucci Anthony S bought 11,500 shares of the company’s common stock on Nov 11 ’24 at a price of $26.82 per share for a total of $0.31 million. Following the purchase, the insider now owns 40284.0 shares.
Celldex Therapeutics Inc disclosed in a document filed with the SEC on Jun 14 ’24 that Martin Samuel Bates (SVP AND CFO) sold a total of 17,172 shares of the company’s common stock. The trade occurred on Jun 14 ’24 and was made at $35.42 per share for $0.61 million. Following the transaction, the insider now directly holds 28125.0 shares of the CLDX stock.
Still, SEC filings show that on Jun 14 ’24, Crowley Elizabeth (SR. VP & CPDO) disposed off 30,000 shares at an average price of $34.87 for $1.05 million. The insider now directly holds 9,074 shares of Celldex Therapeutics Inc (CLDX).
